Boston Scientific Corporation (NYSE:BSX) is a leading medical device company that develops and manufactures a wide range of products used in interventional medical specialties. The company is known for its innovative solutions in areas such as cardiology, endoscopy, and urology. Boston Scientific competes with other major players in the medical device industry, including Medtronic and Johnson & Johnson.
On February 5, 2026, Needham set a price target of $97 for BSX, which was trading at $75.52. This target suggests a potential increase of approximately 28.44% from the current price. The optimism from Needham is supported by Boston Scientific's strong financial performance in the fourth quarter. The company reported revenues of $5.29 billion, slightly surpassing the consensus estimate of $5.28 billion.
Boston Scientific's adjusted earnings per share for the fourth quarter were 80 cents, exceeding both the consensus estimate of 78 cents and the management's guidance of 77 to 79 cents. This strong earnings performance has likely contributed to the positive outlook from analysts like Needham's Mike Matson, who have adjusted their price targets in response to the earnings report.
Looking ahead, Boston Scientific forecasts net sales growth of approximately 10.5% to 11.5% in 2026 on a reported basis, and 10% to 11% organically. The company expects sales between $22.18 billion and $22.38 billion, aligning closely with the consensus of $22.37 billion. This growth outlook further supports the potential for the stock to reach Needham's target price.
Following the earnings announcement, BSX shares rose by 0.6% to $75.92 in pre-market trading. However, the stock is currently priced at $75.45, reflecting a slight decrease of approximately 0.07% with a change of $0.05. Despite this minor fluctuation, the company's market capitalization remains robust at approximately $111.9 billion, indicating strong investor confidence.
